BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients—Frequency and clinical outcome

Leukemia Research - Tập 38 - Trang 454-459 - 2014
Marjanu Hikmah Elias1, Abdul Aziz Baba2, Husin Azlan2, Hassan Rosline3, Goh Ai Sim4, Menon Padmini5, S. Abdul Wahid Fadilah6, Ravindran Ankathil1
1Human Genome Centre, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Malaysia
2Haemato-Oncology Unit, Department of Internal Medicine, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Malaysia
3Hematology Department, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Malaysia
4Hospital Pulau Pinang, Malaysia
5Hospital Raja Permaisuri Bainun, Malaysia
6Medicine Department & Cell Therapy Centre, UKM Medical Centre, Malaysia

Tài liệu tham khảo

Usui, 2004, Molecular targeted treatment – new treatment strategy for patients with chronic myeloid leukemia, Rinsho Byori, 52, 136

Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867

Wu, 2008, Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase, J Natl Cancer Inst, 100, 926, 10.1093/jnci/djn188

Jabbour, 2006, Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate, Leukemia, 20, 1767, 10.1038/sj.leu.2404318

Elias, 2012, Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients, Hematol Rep, 4, e23, 10.4081/hr.2012.e23

Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569

Baccarani, 2009, Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol, 27, 6041, 10.1200/JCO.2009.25.0779

Gorczyca, 2008, 319

Soverini, 2004, Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib, Clin Chem, 50, 1205, 10.1373/clinchem.2004.031112

Press, 2007, A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response, Clin Cancer Res, 13, 6136, 10.1158/1078-0432.CCR-07-1112

Kantarjian, 2006, New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance, Ann Intern Med, 145, 913, 10.7326/0003-4819-145-12-200612190-00008

La Rosee, 2010, Resistance to imatinib: mutations and beyond, Semin Hematol, 47, 335, 10.1053/j.seminhematol.2010.06.005

O’Hare, 2007, Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia, Blood, 110, 2242, 10.1182/blood-2007-03-066936

Corbin, 2002, Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571, J Biol Chem, 277, 32214, 10.1074/jbc.M111525200

Druker, 1996, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med, 2, 561, 10.1038/nm0596-561

Branford, 2003, Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis, Blood, 102, 276, 10.1182/blood-2002-09-2896

Ang, 2008, The M351T BCR-ABL kinase mutation is uncommon in asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels

Kim, 2009, Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent, Hematol Oncol, 27, 190, 10.1002/hon.894

Sherbenou, 2010, BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib, Blood, 116, 3278, 10.1182/blood-2008-10-183665

Qin, 2011, Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients, Ann Hematol, 90, 47, 10.1007/s00277-010-1039-5

Branford, 2009, Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?, Blood, 114, 5426, 10.1182/blood-2009-08-215939

Cang, 2008, P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia, J Hematol Oncol, 1, 15, 10.1186/1756-8722-1-15

Lee, 2008, Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations, Cancer, 112, 1744, 10.1002/cncr.23355

Soverini, 2007, Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain, Haematologica, 92, 401, 10.3324/haematol.10822

Jabbour, 2010, Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history, Leukemia, 24, 6, 10.1038/leu.2009.193

Khoury, 2012, Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure, Blood, 119, 3403, 10.1182/blood-2011-11-390120

Thông tin
Thông tin xuất bản

Leukemia Research

Tập 38

454-459

Thông tin tác giả